AstraZeneca launches Evinova to optimize clinical trials and patient care


AstraZeneca has announced the launch of Evinova, poised to become a leading provider in the digital health solutions domain. Backed by AstraZeneca and collaborating with Parexel and Fortrea, Evinova aims to deliver globally-scaled digital products and services to the life sciences and healthcare sectors.

Evinova’s primary focus will be on marketing proven digital technology solutions, already globally implemented by AstraZeneca, to enhance clinical trial designs and delivery. This initiative is expected to significantly reduce the time and cost of developing new medicines, facilitate patient care at home, and alleviate the burden on health systems. Additionally, Evinova is set to expand into digital remote patient monitoring and digital therapeutics, with a robust pipeline of digital innovations in these areas.

See also  AstraZeneca to sell five hypertension drugs to Atnahs Pharma

Leveraging AstraZeneca’s extensive experience in developing novel therapeutics and insights from patients and clinical researchers, Evinova will offer established technology solutions to pharmaceutical companies, biotechs, and CROs to support global clinical research. These technologies have been instrumental in the successful execution of multiple AstraZeneca-sponsored clinical trials across over 40 countries.

Evinova by AstraZeneca Sets New Standard in Digital Health and Clinical Trials

Evinova by AstraZeneca Sets New Standard in Digital Health and Clinical Trials

Pascal Soriot, CEO of AstraZeneca, emphasized the potential of digital solutions in accelerating medicine development. He highlighted Evinova’s unique combination of scientific expertise and prowess in developing AI-enabled digital technologies at scale, aimed at enhancing patient care, driving healthcare transformation, and reducing carbon emissions.

See also  AstraZeneca and Imperial spin-off VaxEquity enter into saRNA partnership

Cristina Duran, President of Evinova, expressed enthusiasm about introducing AstraZeneca’s globally-scaled digital solutions to the wider life sciences community. She emphasized the importance of digital solutions in supporting healthcare professionals, regulators, and patients. Evinova’s experience and evidence-led approach are expected to improve patient experiences and outcomes significantly.

Prominent CROs Parexel and Fortrea have agreed to integrate Evinova’s digital health solutions into their offerings. Evinova also collaborates with Accenture and Amazon Web Services to further industry adoption and expand its global reach.

See also  FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia treatment

Evinova will blend clinical and regulatory experience from AstraZeneca with its deep expertise in digital technology, covering strategy and development, digital product development, data science and AI, user experience design, and behavioral science. In addition to digital solutions, Evinova will provide custom scientific solutions, including remote patient monitoring, novel endpoint solutions, trial design, and consulting services.

Share This